Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD19. The page also collects GeneMedi's different modalities and formats products for CD19 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD19 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Target IDGM-T56365
Target NameCD19
Gene ID930
Gene Official NameCD19
Gene AliasB4, CVID3
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Immuno-oncology Target


Pre-made CD19-specific INN-index biosimilar (antibody&conjugates)-lisocabtagene maraleucel, obecabtagene autoleucel, Obexelimab, brexucabtagene autoleucel, zamtocabtagene autoleucel, tisagenlecleucel, axicabtagene ciloleucel, Coltuximab, Loncastuximab, taplitumomab paptox, Tafasitamab, azercabtagene zapreleucel, Blinatumomab, acmucabtagene autoleucel, evoncabtagene pazurgedleucel, Inebilizumab, Ensomafusp, relmacabtagene autoleucel, coltuximab ravtansine, loncastuximab tesirine, Denintuzumab, tebrocabtagene autoleucel, ensomafusp alfa, vadacabtagene leraleucel, denintuzumab mafodotin, Duvortuxizumab

Anti-CD19 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-INN-894lisocabtagene maraleucelCD19Engineering T cellINN mab
GMP-Bios-INN-930obecabtagene autoleucelCD19Engineering T cellINN mab
GMP-Bios-ab-383Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyObexelimabCD19Whole mAbINN mab
GMP-Bios-INN-766brexucabtagene autoleucelCD19Engineering T cellINN mab
GMP-Bios-INN-1054zamtocabtagene autoleucelCD19Engineering T cellINN mab
GMP-Bios-INN-1023tisagenlecleucelCD19Engineering T cellINN mab
GMP-Bios-INN-744axicabtagene ciloleucelCD19Engineering T cellINN mab
GMP-Bios-ab-116Pre-Made Coltuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyColtuximabCD19Whole mAb ADCINN mab
GMP-Bios-ab-320Pre-Made Loncastuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyLoncastuximabCD19Whole mAb ADCINN mab
GMP-Bios-INN-1008Pre-Made Taplitumomab Paptox biosimilar, Fusion Protein, Taplitumomab-Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody staplitumomab paptoxCD19Fusion ProteinINN mab
GMP-Bios-ab-543Pre-Made Tafasitamab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyTafasitamabCD19Whole mAbINN mab
GMP-Bios-INN-745azercabtagene zapreleucelCD19Engineering T cellINN mab
GMP-Bios-ab-074Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibodyBlinatumomabCD19;CD3EBispecific T-Cell EngagerINN mab
GMP-Bios-INN-716acmucabtagene autoleucelCD19Engineering T cellINN mab
GMP-Bios-INN-847evoncabtagene pazurgedleucelCD19Engineering T cellINN mab
GMP-Bios-ab-273Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyInebilizumabCD19Whole mAbINN mab
GMP-Bios-ab-664Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3EnsomafuspCD19Fusion ProteinINN mab
GMP-Bios-INN-971relmacabtagene autoleucelCD19Engineering T cellINN mab
GMP-Bios-INN-786Pre-Made Coltuximab Ravtansine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugatecoltuximab ravtansineCD19Whole mAb ADCINN mab
GMP-Bios-INN-896Pre-Made Loncastuximab Tesirine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugateloncastuximab tesirineCD19Whole mAb ADCINN mab
GMP-Bios-ab-139Pre-Made Denintuzumab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibodyDenintuzumabCD19Whole mAb ADCINN mab
GMP-Bios-INN-1010tebrocabtagene autoleucelCD19Engineering T cellINN mab
GMP-Bios-INN-836Pre-Made Ensomafusp Alfa  Alfaiosimilar, Bispecific, Anti-Cd19; Tnfrsf9 Antibody: Anti-B4/CVID3;ILA/4-1BB/CDw137 therapeutic antibodyensomafusp alfaCD19;TNFRSF9BispecificINN mab
GMP-Bios-INN-1041vadacabtagene leraleucelCD19Engineering T cellINN mab
GMP-Bios-INN-800Pre-Made Denintuzumab Mafodotin Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugatedenintuzumab mafodotinCD19Whole mAb ADCINN mab
GMP-Bios-ab-161Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibodyDuvortuxizumabCD19;CD3EBispecific scFv with CrossoverINN mab



Pre-made anti-CD19 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD19 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD19 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T56365-AbAnti-CD19 monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×